| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-056 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于控股股东及其一致行动人减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 控股股东及其一致行动人的基本情况 截至本公告披露日，益丰大药房连锁股份有限公司（以下简称"公司"）控股 股东宁波梅山保税港区厚信创业投资合伙企业（有限合伙）（以下简称"厚信创投"） 持有公司无限售流通股 262,492,776 股，占公司当前总股本 21.65%。 公司控股股东厚信创投的一致行动人宁波梅山保税港区益之丰企业管理合 伙企业（有限合伙）（以下简称"益之丰"）持有公司无限售流通股 12,692,782 股， 占公司当前总股本 1.05%。 公司控股股东厚信创投的一致行动人宁波梅山保税港区益仁堂企业管理合 伙企业（有限合伙）（以下简称"益仁堂"）持有公司无限售流通股 5,816,466 股， ...

Group 1 - The controlling shareholder of Yifeng Pharmacy, Houxin Chuangtou, along with its concerted parties, plans to reduce their holdings by up to 2% of the company's total shares due to employee funding needs [1] - The total number of shares to be reduced is up to 24,248,336 shares [1]

Core Viewpoint - Yifeng Pharmacy (603939) announced that Huxin Chuangtou, Yizhi Feng, and Yiren Tang plan to collectively reduce their holdings by no more than 2% of the company's shares [1] Group 1 - The total planned reduction in shareholding is capped at 2% [1]

A股医药商业板块水下拉起，一心堂封板涨停，漱玉平民、健之佳、华人健康、第一医药、益丰药房等 跟涨。 ...

Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of its 2024 annual equity distribution plan, resulting in a decrease from 32.54 CNY to 32.14 CNY per share [1][3]. Group 1: Bond Information - The convertible bond, referred to as "益丰转债," was publicly issued on March 4, 2024, and listed on the Shanghai Stock Exchange on March 27, 2024 [1]. - The bond has a maturity period of 6 years, from March 4, 2024, to March 3, 2030, with a conversion period from September 8, 2024, to March 3, 2030 [1]. Group 2: Equity Distribution Details - The company plans to distribute a cash dividend of 0.40 CNY per share (including tax) to all shareholders, with the record date set for June 17, 2025, and the ex-dividend date on June 18, 2025 [2]. - The adjustment to the conversion price is based on the company's equity distribution plan, which includes provisions for adjusting the conversion price in the event of cash dividends, stock dividends, or other equity changes [2]. Group 3: Conversion Price Adjustment - The conversion price adjustment formula is specified in the company's prospectus, detailing how the price will be recalculated based on various equity distribution scenarios [2]. - The adjusted conversion price of 32.14 CNY per share will take effect on June 18, 2025, following the equity distribution [3]. - The convertible bonds will be suspended from conversion from June 11, 2025, to June 17, 2025, and will resume conversion on June 18, 2025 [3].

Key Points - The company announced a cash dividend of 0.40 CNY per share for A shares [1][2] - The dividend distribution was approved at the annual shareholders' meeting on May 29, 2025 [1] - The total cash dividend to be distributed amounts to approximately 484.97 million CNY based on the total share capital of 1,212,416,854 shares [1][2] Relevant Dates - The record date for the dividend is June 17, 2025, with the ex-dividend date on June 18, 2025, and the payment date also on June 18, 2025 [2][3] Distribution Implementation - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [2] - The distribution does not involve the issuance of bonus shares or capital increase [2] Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.40 CNY per share [3][4] - For shares held for less than one year, the tax rate varies based on the holding period, with a maximum effective tax rate of 20% for shares held for one month or less [3][4] - For Hong Kong investors, the net cash dividend after a 10% withholding tax will be 0.36 CNY per share [4]

益丰大药房连锁股份有限公司 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 关于因权益分派调整可转债转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因公司拟实施 2024 年度权益分派方案，根据《上海证券交易所股票上市规则》等有关规 定，权益分派公告披露前一交易日(2025 年 6 月 11 日)至权益分派股权登记日(2025 年 6 月 17 日)期间，本公司可转债停止转股。本公司的相关证券复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 113682 | 益丰转债 | 可转债转股复牌 | | | 2025/6/17 | 2025/6/18 | 一、转股价格调整依据 益丰大 ...

证券代码：603939 证券简称：益丰药房 公告编号：2025-054 债券代码：113682 债券简称：益丰转债 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 29 日的2024年年度股东会审议通过。 益丰大药房连锁股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.40元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/17 | － | 2025/6/18 | 2025/6/18 | 差异化分红送转： 否 二、 分配方案 截至股权登记日 2025 年 6 月 17 日下午上海证券交易所收市后，在中国证券登记结算 有限责任公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本1,21 ...

Summary of Key Points from Conference Call Records Industry Overview - The conference call primarily discusses the convertible bond market in China, highlighting recent performance trends and investment strategies related to this sector [1][5][25]. Core Insights and Arguments 1. **Recent Performance of Convertible Bonds**: The convertible bond market has shown strong performance, particularly from late April to early June, with notable gains in weighted convertible bonds and high-yield assets like Reborn Technology and Huahong Technology [1][5]. 2. **Market Dynamics**: Two main forces have driven the valuation of convertible bonds upward: the rise of weighted assets from late April to early May and the performance of low valuation and high-yield assets from mid-May to early June [1][7]. 3. **Investment Strategies**: The investment focus is on high-dividend assets and large-cap institutional favorites, with a structural market outlook suggesting a range-bound trading environment [2][22]. 4. **Future Fund Flows**: The inflow of narrow-band incremental funds is expected to be influenced by the ongoing Sino-US trade negotiations and the yield rates of long and short-term government bonds [1][8]. 5. **Valuation Trends**: The China Convertible Bond Index is nearing historical highs, but the momentum for further increases may slow due to high valuations of certain convertible bonds and the approaching strong redemption period for bank convertible bonds [9][25]. Additional Important Insights 1. **Risk Management**: Emphasis on controlling drawdown risks by selecting convertible bonds with lower valuation indices and those that correspond to lower stock drawdowns [11]. 2. **AI in Research**: The application of AI technology in analyzing convertible bonds has improved research efficiency and accuracy, aiding in the identification of market trends and investment opportunities [12][14]. 3. **Sector Recommendations**: Recommendations include focusing on the banking sector and specific chemical sub-sectors, with suggestions for diversified investments in liquid large-cap banks and emerging fields like Chengheng and Liying [3][22]. 4. **Market Sentiment**: The sentiment around the convertible bond market is cautiously optimistic, with expectations of continued interest from institutional investors in small and mid-cap convertible bonds [4][8]. Conclusion The conference call provides a comprehensive overview of the current state and future outlook of the convertible bond market in China, emphasizing recent performance trends, investment strategies, and the impact of macroeconomic factors on fund flows and valuations. The insights gathered highlight both opportunities and risks within the sector, guiding potential investment decisions.

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-053 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 风险提示：本次触发转股价格修正条件的期间从 2025 年 5 月 26 日起算，截 至 2025 年 6 月 9 日，益丰大药房连锁股份有限公司（以下简称"公司"、"本 公司"）股票已有 10 个交易日的收盘价低于当期转股价格的 85%，预计将触发 转股价格向下修正条件。若触发条件，公司将于触发条件当日召开董事会审议决 定是否向下修正转股价格，并及时履行信息披露义务。敬请广大投资者注意投资 风险。 一、 "益丰转债"发行上市概况 经中国证券监督管理委员会证监许可[2024]109 号文同意注册，公司于 2024 年 3 月 4 日向不特定对象发行了 1,797.4320 万张可转换公司债券，每张面值 100 元，发行总额 179,743.20 万元。债券期限为发行之日起六年（自 2024 年 3 月 4 日至 2030 年 3 月 3 日），债券票面利率为：第一年 0.30%、第二年 0.50%、 ...